ARC-IM Adaptive Neurostimulation for Parkinson's Disease
Overview
flowchart TD
ARC["ARC"] -->|"activates"| BDNF["BDNF"]
ARC["ARC"] -->|"participates in"| neurotrophin_signaling["neurotrophin signaling"]
ARC["ARC"] -->|"activates"| FOS["FOS"]
ARC["ARC"] -->|"regulates"| Aging["Aging"]
ARC["ARC"] -->|"participates in"| synaptic_plasticity["synaptic plasticity"]
ARC["ARC"] -->|"produces"| NPY["NPY"]
ARC["ARC"] -->|"produces"| AGRP["AGRP"]
ARC["ARC"] -->|"produces"| POMC["POMC"]
ARC["ARC"] -->|"therapeutic target"| Oxidative_Stress["Oxidative Stress"]
ARC["ARC"] -->|"regulates"| SYNAPSE["SYNAPSE"]
ARC["ARC"] -->|"activates"| CREB1["CREB1"]
ARC["ARC"] -->|"regulates"| Ms["Ms"]
ARC["ARC"] -->|"associated with"| Als["Als"]
ARC["ARC"] -->|"regulates"| Obesity["Obesity"]
style ARC fill:#4fc3f7,stroke:#333,color:#000
ARC-IM (Adaptive Remote Controller - Implantable Module) is an innovative closed-loop deep brain stimulation (DBS) system developed through a collaboration between the École Polytechnique Fédérale de Lausanne (EPFL) and Neuroloop GmbH. This clinical trial represents a significant advancement in neurostimulation therapy for Parkinson's disease by implementing adaptive, biomarker-driven stimulation that adjusts in real-time to patient symptoms["@nct"][@priori2023].
...
ARC-IM Adaptive Neurostimulation for Parkinson's Disease
Overview
Mermaid diagram (expand to render)
ARC-IM (Adaptive Remote Controller - Implantable Module) is an innovative closed-loop deep brain stimulation (DBS) system developed through a collaboration between the École Polytechnique Fédérale de Lausanne (EPFL) and Neuroloop GmbH. This clinical trial represents a significant advancement in neurostimulation therapy for Parkinson's disease by implementing adaptive, biomarker-driven stimulation that adjusts in real-time to patient symptoms["@nct"][@priori2023].
Traditional DBS systems deliver constant high-frequency stimulation regardless of the patient's current state, which can lead to side effects and inefficient battery use. The ARC-IM system addresses these limitations by continuously monitoring neural signals and adjusting stimulation parameters automatically, providing a more personalized and effective treatment approach.
Clinical Trial Details | Attribute | Value |Trial ID | NCT06295614 |Sponsor | EPFL / Neuroloop Collaboration |Phase | Phase 1/2 |Status | RECRUITING |Condition | Parkinson's Disease |Intervention | Adaptive Deep Brain Stimulation |Target Brain Region | Subthalamic nucleus or Globus pallidus internus |Estimated Enrollment | 20-30 patients |
Background
Limitations of Conventional DBS Traditional deep brain stimulation for Parkinson's disease has been transformative, but has inherent limitations:
Fixed Stimulation: Delivers constant high-frequency stimulation (130-180 Hz) regardless of patient activity stateSide Effects: Can cause speech difficulties, gait disturbances, and cognitive issuesNo Adaptation: Cannot respond to diurnal fluctuations in symptomsPostural Effects: Stimulation may worsen dyskinesias or postural instabilityBattery Drain: Continuous high-power stimulation shortens device lifespanThe Promise of Adaptive DBS Adaptive (closed-loop) DBS represents the next evolution in neurostimulation:
Biomarker-Driven: Uses neural signals to detect symptom statesReal-Time Adjustment: Modulates stimulation based on current needsReduced Side Effects: Lower average stimulation intensityImproved Efficacy: Better symptom control throughout the dayPersonalized Therapy: Adapts to individual patient patternsARC-IM Technology
System Components The ARC-IM system consists of several integrated components:
Implantable Pulse Generator (IPG) Miniaturized neurostimulator
Rechargeable battery
Wireless communication
Sensing Electrodes Dedicated contacts for local field potential (LFP) recording
Positioned to detect pathological oscillations
Continuous neural monitoring capability
Processing Algorithm Real-time signal analysis
Beta oscillation detection
Movement-related desynchronization identification
Artifact rejection
Adaptive Controller Decision algorithm for stimulation adjustment
Smooth parameter transitions
Patient-specific tuning
Key Neural Biomarkers The ARC-IM system monitors several neural signatures:
Beta Oscillations (13-35 Hz)
Elevated in the motor [cortex](/brain-regions/cortex) and basal ganglia of PD patients
Correlate with rigidity and bradykinesia
Suppressed by effective dopaminergic therapy
Primary trigger for increasing stimulation
Mu rhythm suppression during movement
Indicates successful motor execution
Used to reduce stimulation during voluntary movement
Other Biomarkers (Future Development)
Tremor-related oscillations
Gait-related patterns
Sleep state indicators
Clinical Trial Objectives
Primary Objectives
Assess safety and tolerability of adaptive DBS
Determine optimal biomarker thresholds
Validate real-time signal processing accuracy
Secondary Objectives
Compare adaptive vs. conventional DBS efficacy
Evaluate quality of life improvements
Assess battery longevity
Exploratory Objectives
Machine learning optimization
Long-term biomarker stability
Adaptive protocols for non-motor symptoms
Inclusion Criteria
Age 40-75 years
Diagnosis of idiopathic Parkinson's disease
Disease duration >5 years
Motor complications inadequately controlled by medication
Eligible for DBS surgery (no contraindications)
Stable dopaminergic medication for 4+ weeks
Exclusion Criteria
Significant cognitive impairment
Psychiatric comorbidities
Previous brain surgery
Active implants (pacemakers, etc.)
Unable to comply with study procedures
Expected Outcomes The ARC-IM trial aims to demonstrate:
Superior Symptom Control: Better Unified Parkinson's Disease Rating Scale (UPDRS) scores compared to conventional DBSReduced Side Effects: Lower incidence of speech, gait, and cognitive adverse eventsImproved Quality of Life: Better scores on PDQ-39 and other quality of life measuresExtended Battery Life: Longer time between replacements due to reduced average stimulation
Clinical Significance The ARC-IM adaptive DBS system represents several important advances:
Personalized Medicine: Algorithm adapts to individual neural patternsClosed-Loop Technology: First fully implantable adaptive DBS systemBiomarker Validation: Further validates beta oscillations as therapeutic targetsTechnology Platform: Adaptable to other neurological disorders
Future Directions
Integration with sensing-enabled pacemakers
Sleep-wake cycle adaptation
Multi-center deployment
FDA and CE marking approvals
Related Pages
[Parkinson's Disease](/diseases/parkinsons-disease)
[Deep Brain Stimulation](/technologies/deep-brain-stimulation)
[Subthalamic Nucleus](/cell-types/subthalamic-nucleus)
[Globus Pallidus](/brain-regions/globus-pallidus)
[Basal Ganglia](/brain-regions/basal-ganglia)
[Neurostimulation](/technologies/neurostimulation)
See Also
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
External Links
[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
Unknown, NCT06295614 - Adaptive Deep Brain Stimulation in Parkinson's Disease (n.d.)
[Priori A et al, Adaptive deep brain stimulation: a novel approach to Parkinson's disease treatment (2023)](https://doi.org/10.1016/j.clinph.2023.03.009)
Pathway Diagram The following diagram shows the key molecular relationships involving ARC-IM Adaptive Neurostimulation for PD discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)
Show full description